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members with a cholesterol marker in their profile were invited to participate via
email; enrollment was supplemented with digital outreach. Interested individuals
clicked a link to access study information and screen based on self-reported diag-
nosis and willingness to have data linked to the SAIL warehouse. Study subjects
completed an on-line questionnaire and provided identifiers to be used only for
data linkage. The SAIL system’s NHS Trusted Third Party converted study identifi-
ers into pseudo-identifiers allowing the linkage of patient-reported data with elec-
tronic health data. RESULTS: A total of 240 enrolled within 6 weeks: 98 fromMedi-
Guard and 142 through other digital channels. NHS matched 226 of 240 (94%) to a
pseudo-identifier (69 exactly, 157with probability0.9). A total of 91 of 226matched
(41%) had at least one primary care record in SAIL and nearly all (89 of 91, 98%) had
data suggesting a cholesterol problem.Matching cholesterol test dates (6months)
were located for 66 of 89 (74%, Spearman correlation0.786, p0.0001) and there
was a high positive correlation of total cholesterol values amongst the 1/3 of pa-
tients able to self-report data (n28, Pearson correlation0.785, P0.0001). Addi-
tional analyses exploring markers that predict patient’s ability to self-report are
underway. CONCLUSIONS: This study demonstrates the feasibility of linking pa-
tient reported data with electronic health information. UK individuals are inter-
ested in participating, provide truthful information, and their patient-reported
data can be linked to electronic information in the SAIL warehouse in Wales, thus
offering new research possibilities.
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OBJECTIVES: To determine the relationship between postsurgical opioid use
through morphine equivalent dose (MED) and ileus was assessed in patients un-
dergoing commonGI surgeries, and the impact of ileus on length of stay (LOS), total
visit cost, and 30-day readmissions.METHODS: The Premier database was queried
to identify adult inpatients discharged between 2008 and 2010 who received post-
surgical opioids following open colectomy, laparoscopic colectomy or cholecystec-
tomy. Ileus was identified using ICD-9 diagnosis codes and postsurgical (MED) was
calculated. Descriptive statistics including the outcomes of LOS, total visit cost, and
30-day readmissionwere obtained. For comparing patients with andwithout ileus,
t-tests for continuous variables and chi-squared tests for categorical variableswere
used (alpha 0.05). RESULTS: There were 138,068 patients, average age of 56.8 (SD
18.5) that met the study criteria. Overall, 10.3% of patients had an ileus, ranging
from 3.2% in laparoscopic cholecystectomy to 20.6% in open colectomy. The unad-
justed mean LOS (7.3 days p0.0001), total visit cost ($15,928 p0.0001), and
readmissions (5.9% p0.0001) were higher for patients with ileus compared to
those without ileus. Of note, the total visit costs were 3 times higher among pa-
tients experiencing an ileus after laparoscopic cholecystectomies compared to 2
times greater for other GI procedures complicated by ileus, than patients without
ileus. Patients with higher (abovemedian) MED compared to lower (belowmedian)
MED had a 2 fold greater odds of ileus (OR 2.0 95% CI 1.92 – 2.06; p 0.0001).
CONCLUSIONS: Occurrence of ileus significantly increased the total cost across all
GI surgeries even in surgeries where the incidence of ileus is less common. In this
study, higher dosages of opioids are associated with the incidence of ileus; more
research is needed to determine whether strategies to decrease opioid use im-
proves outcomes and reduces ileus.
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OBJECTIVES: To quantify the incidence of hepatotoxicity associated with antithy-
roid drugs and analyze the relative hepatotoxicity risk of methimazole (MMI) and
carbimazole (CBM) compared to propylthiouracil (PTU) among patients with
hyperthyroidism. METHODS: A retrospective population-based cohort study was
conducted by analyzing data from the Taiwan National Health Insurance Research
Databases between January 1, 2004 andDecember 31, 2008. Patients diagnosedwith
hyperthyroidism (ICD-9-CM codes 242.xx, 775.3) and initially receiving antithyroid
drugs were identified as the study cohort, in which MMI/CBM and PTU users were
further specified. The two groups were followed up to observe the occurrence of
hepatotoxic events, including jaundice, cholestasis, noninfectious hepatitis, acute
liver failure, and liver transplant. Crude incidence rates of the hepatotoxicity per
1000 person-years were calculated. Cox proportional hazard models were em-
ployed to estimate crude and adjusted hazard ratios (HRs) of hepatotoxicity risks
for MMI/CBM relative to PTU. RESULTS: The study cohort comprised a total of
71,379 patientswith hyperthyroidism. The hepatitis outcomewas observed to have
the highest incidence in bothMMI/CBM and PTU users, with a rate of 11.44 and 9.89
events per 1000 person-years, respectively. The comparative risk analyses indi-
cated that use of MMI/CBM exerted a significantly increased risk of hepatitis than
use of PTU (adjusted HR, 1.23; 95% CI, 1.03-1.47). Additionally, MMI/CBM prescribed
at an average daily dose greater than 10 mg further enhanced the risk of jaundice
(adjusted HR, 1.99; 95% CI, 1.13-3.49) and hepatitis (adjusted HR, 2.33; 95% CI, 1.93-
2.82) to a larger degree than any use of PTU. CONCLUSIONS: Hepatitis is the most
frequently occurring hepatotoxicity outcome for both MMI/CBM and PTU users.
Notably, MMI/CBM is associated with a higher risk of hepatitis than PTU in a dose-
dependent manner. Health care professionals should be vigilant to the symptoms
of hepatitis for patients prescribed antithyroid drugs, especially for those receiving
higher doses of MMI/CBM.
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OBJECTIVES: To develop and validate algorithms that can identify diverticulitis
patients with high reliability through the use of electronic medical records (EMRs).
METHODS:UsingKPSC EMRs of adults (18 years old)with ICD-9 diagnosis codes of
diverticulitis (562.11, 562.13) between January 1, 2008 and August 30, 2009, we gen-
erated random samples for pilot-testing (N700) and validation purposes
(N1,300) respectively. Both samples were stratified by inpatient (IP), emergency
room (ER), and outpatient (OP) treatment settings. For each setting, we constructed
and analyzed 10 different algorithms based on EMR variables such as diverticulitis
diagnosis code, antibiotics use, computed tomography (CT), and prior diverticulo-
sis diagnosis. Evidence of diverticulitis was verified and confirmed throughmanual
chart review by trained research associates. Agreement between each EMR algo-
rithm and chart confirmation was compared by estimating sensitivity and positive
predictive value (PPV). We defined acceptable sensitivity and PPV as 80%.
RESULTS: ICD-9 diagnosis in combinationwith use of antibiotics within 7 dayswas
the most accurate algorithm to identify diverticulitis in patients treated in OP and
ER settings. For those admitted inpatients, the most accurate algorithm was the
combination of diagnosis code with lower abdominal CT recorded within 7 days of
diagnosis. In the pilot-testing sample, sensitivity and PPV were (94.7%, 81.7%),
(79.1%, 88.7%), and (86.7%, 82.8%) for OP, ER, and IP, respectively. In the validation
sample, sensitivity and PPV remained very high: (85.6%, 96.1%), (91.5%, 94.4%), and
(79.1%, 81.2%) for OP, ER, and IP, respectively. CONCLUSIONS: The KPSC algorithms
developed to identify diverticulitis cases using EMR resulted in high accuracy for
three different treatment settings. The validity of these algorithms should be fur-
ther evaluated in other systems.
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OBJECTIVES: In a field wheremany disciplines, such as clinicians, epidemiologists,
economists and statisticians, interact frequently, a tool to communicate drug
treatment patterns clearly and effectively through graphical means is a necessity-
.Using data visualization techniques, we aim to clearly present treatment patterns
among patients with ulcerative colitis (UC). METHODS: Using the 100% national
Medicare data with Part D information, patients over age 65 with at least one UC
diagnosis were selected for the study. We identified patients who initiated therapy
with tumor necrosis factor (TNF) and non-TNF therapies. For 2 years after the
initiation of biologics, we determined the treatment patterns such as switching to
another TNF, non-TNF, and discontinuation. Using a processing language, we cre-
ated a data visualization tool to demonstrate how patients change their drug pat-
tern after first, second and third switches. RESULTS: A total of 1643 UC patients
initiated their therapy with a TNF agent. 3.47% of these patients switched to an-
other TNF, 1.40% switched to a non-TNF, 61.17% discontinued their therapy, and
33.96% continued their initial therapy. Among patients who switched to another
TNF, 49.12% remained on the switched therapy, 40.35% discontinued therapy,
10.53% switched to another TNF, and no patients switched to a non-TNF. 2,628 UC
patients initiated their therapy with a non-TNF, of which 0.49% switched to an
anti-TNF, 0.19% switched to non-TNF, 97.98% discontinued therapy and 1.33% con-
tinued their initial therapy. CONCLUSIONS: Treatment patterns can be difficult to
present, especially when analyzing several data years and among various switch-
ing patterns. Data visualization tools can help researchers present complicated
results, such as treatment patterns, effectively to a varied audience.
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OBJECTIVES: In health outcomes research, wheremany different disciplines inter-
act frequently, a tool to communicate treatment patterns clearly and effectively
through graphical means is a necessity. Using data visualization techniques, we
aimed to present treatment patterns of patients with Crohn’s disease in a visual
manner. METHODS: This study used 100% national Medicare data with Part D
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information for patients over age 65 with at least one diagnosis for Crohn’s dis-
ease. Patients who initiated therapy with tumor necrosis factor (TNF) and non-
TNF agents were identified. We examined the treatment patterns such as
switching to another TNF, switching to a non-TNF, and discontinuation for two
years after the initiation of TNF biologics. We created a data visualization tool
help visualize how patients change their treatment patterns after first and sec-
ond switches. RESULTS: A total of 3287 Crohn’s disease patients initiated therapy
with a TNF medication. 4.23% of these patients switched to another TNF, 1.00%
switched to a non-TNF, 60.42% discontinued therapy and 34.35% continued
their initial therapy. Among patients who switched to another TNF, 48.20%
continued the switched therapy, 41.01% discontinued, 10.07% switched to an-
other TNF, and 0.72% switched to a non-TNF. A total of 2,140 Crohn’s disease
patients initiated their therapy with a non-TNF, of which 0.89% switched to an
anti-TNF, 0.37% switched to a TNF, 97.38% discontinued therapy, and 1.36%
continued their initial therapy. CONCLUSIONS: When analyzing subsequent
years and switches, treatment patterns can be difficult to capture. Data visual-
ization tools can help present these complicated flows effectively for a diverse
health outcomes research audience.
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OBJECTIVES: Somepatients on prescription proton pump inhibitors (PPIs) continue
to experience breakthrough gastroesophageal reflux disease (GERD) symptoms and
use supplemental over the counter (OTC)medications. This study aimed to identify
factors associatedwith experience of breakthrough symptoms andOTCuse among
prescription PPI users. METHODS: A patient/physician survey and chart review
was conducted in GERD patients currently taking a prescription PPI. Patient [age,
gender, race, body mass index (BMI)], GERD (current severity, years since diagno-
sis), and PPI (directions to take 30-60 minutes prior to eating, daily dose, dosing
frequency) characteristics in addition to self-reported patient behaviors [actually
taking PPIs 30-60 minutes prior to eating; count of missed doses, and doses taken,
but not taken according to directions out of last 10) were considered for model
selection for OTC use and breakthrough symptoms. RESULTS: A total of 501 pa-
tients with mean age 51 years, 37% male, 81% Caucasian, 38% with college degree,
and 16% erosive versus 56% nonerosive GERD (28% undocumented) were enrolled
in the study. Overall, 40%ofpatients reported takinganOTCmedication inaddition to
their PPI. While experiencing breakthrough symptoms was the only significant pre-
dictor of OTC use (OR 5.53, p0.001), nonadherence to directions was associated with
a 14% increase in likelihood of OTC use (p0.07). Seventy-three percent of patients
reported experiencing1 breakthrough symptom. Overweight (OR/CI: 0.50/0.29-0.86)
and obese (OR/CI: 0.57/ 0.34-0.96) patients were less likely to report breakthrough
symptoms compared to normal/underweight patients, while a 1 unit increase in
missed doses was associated with a 41% increased likelihood of breakthrough symp-
toms.Nonadherence todirectionsand timesincediagnosisweresignificantpredictors
inbivariate comparisons, but lost significance in logisticmodels.CONCLUSIONS:This
study suggests real-world patient-reported medication adherence may be associ-
ated with fewer breakthrough symptoms. This highlights the importance and the
impact of medication-taking behavior on patient outcomes.
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OBJECTIVES: Published evidence on the prevalence of non-steroidal anti-inflam-
matory drug (NSAID) and gastroprotective agent (GPA) use in the United States (US)
is lacking. We examined the prevalence of GPA use among arthritis patients using
NSAIDs.METHODS: Aweb-based community panel of men and women age40 in
theUnited Stateswith self-reported arthritiswas invited via e-mail to participate in
a web-based survey. Panelists interested in participating provided consent and
completed the survey. Only participantswho reported using anNSAID in the last 30
days were eligible. Questions regarding NSAID and GPA use (medication/dosage/
frequency/duration of use) were asked, as were comorbid conditions, gastrointes-
tinal history, and other risk factors. RESULTS: Two thousand met the inclusion
criteria and completed the survey (54% response rate). Themajority of participants
had osteoarthritis (n1525, 76%), 354 (18%) had rheumatoid arthritis, and 121 (6%)
had both. Mean age was 62.0 years; 64% were female; 83% were Caucasian; 25%
worked full-time and 39% were retired. The majority (92%) had health insurance,
with half covered by Medicare/Medicaid. Mean time with arthritis was 13.0 years;
47% and 19% experienced arthritis symptoms “daily” and “almost always”, respec-
tively. The most frequently-used NSAIDs were ibuprofen (54%), aspirin (35%) and
naproxen (33%). Nearly 43% reported using a GPA with 86% (n731) reporting use
more often than three times per month. The most frequently-used GPAs were
omeprazole (48%), ranitidine (17%) and esomeprazole (17%). Of daily NSAID users,
42% reported taking a GPA. Of non-GPA users, 12% reported a history of gastro-
esophageal reflux disease, 9% reported a history of ulcers, and 3% reported a his-
tory of gastrointestinal bleeding. CONCLUSIONS: This is the first study in the
United States to document NSAID and GPA use. Importantly, only 42% of daily
NSAID users take GPAs on a routine basis, leaving the majority of NSAID users at
risk for gastrointestinal complications.
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OBJECTIVES: Dexlansoprazole, a once-daily proton pump inhibitor (PPI) in a Dual
Delayed Release formulation has demonstrated efficacy in a phase 3b study in
maintaining symptom control among gastroesophageal reflux disease (GERD) pa-
tients previously controlled on twice daily (BID) PPIs. A pharmacy budget impact
model (BIM) from a US payer perspective was developed to assess the impact of
switching GERD patients from BID PPIs to QD dexlansoprazole over a three-year
period. METHODS: An excel-based BIM on a hypothetical plan of 1 million mem-
bers was developed. Based on published literature, 28% of members had GERD,
among which 57% were prescribed PPI therapy. Among these, 74%, 23% and 3% of
patientswere onQD, BID and as needed PPI therapy, respectively. The proportion of
patients switching from BID PPI to QD dexlansoprazole and efficacy of dexlanso-
prazole in achieving symptom control among those patientswas assumed to range
from 84%-88% based on the results of the phase 3b trial. Market share of PPIs and
drug costs were derived using internally available data. The market share of dex-
lansoprazole in year 1 was 4.23% and 8.44% pre- and post-switching, respectively.
Model outcomes for years 1, 2 and 3 included: net total and permember per month
(PMPM) pharmacy savings. RESULTS: The net pharmacy saving from switching to
QD dexlansoprazole was estimated to be $7.9, $6.4 & $5.9 million for years 1, 2, & 3,
respectively. PMPM pharmacy cost savings ranged from $0.66 in year 1 to $0.50 in
year 3. The model results were most sensitive to cost of esomeprazole, proportion
of GERD patients on PPI, prevalence of the disease, and proportion of patients
switching from BID esomeprazole to QD dexlansoprazole. CONCLUSIONS: Based
on the economic model, switching GERD patients from twice daily PPIs to QD dex-
lansoprazole may generate cost savings for US health plans.
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OBJECTIVES: Highly effective biologic therapies offer new treatment options for
patients suffering from moderate to severe ulcerative colitis (UC) who fail with
conventional therapies. A budget impact model was constructed to estimate the
costs of infliximab therapy for steroid-dependent, steroid-refractory and acute UC
patients in the perspective of Croatia. METHODS: Using epidemiology data and
medical treatment guidelines, a budget impactmodel was constructed to calculate
the annual cost of infliximab according to the Croatian Guidelines for Treatment of
UC. Moderate to severe UC patients that were diagnosed steroid-dependent, and
acute or steroid-refractory patients that were non-responsive to IV corticosteroids
were considered eligible for infliximab. Clinical trial data was applied to the guide-
lines to determine infliximab eligible patients. Sensitivity analysis was conducted
to describe the ranges of costs by varying incidence, and dosing, considering drug
wastage. RESULTS: According to the epidemiology data, 17.8% (411 patients) of all
UC patients fall into these 3 categories of patients and should be treated with
infliximab. Total costs of treating these patients according to drafted guidelines
would be 33,822,366 kn (0.01% of GDP, 0.13% of total healthcare costs or 0.50% of
total pharmaceutical sales for 2010), 19,329,407 kn (57.15%) of which is attributed to
steroid-dependent patients, 7,893,089 kn (23.34%) to steroid-refractory and
6,599,870 kn (19.51%) to acute patients. New patients who require 8 infusions
within the first year account for 11% of the cost, whereas maintenance therapy
patients receiving 6 infusions explain the rest. Adjusting the dosage from400mg/kg
to 350mg/kg decreases the total cost by 12.50% (4,227,796 kn). A decreasing inci-
dence of UC patients from 5.9 to 3.9 per 100,000 reduces the cost by 4.69% (1,586,046
kn). CONCLUSIONS: Given the significant improvement in quality of life of those
with UC, infliximab should be considered where the budget allows it. Steroid-
refractory UC patients accounted for majority of the costs.
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OBJECTIVES: To evaluate the costs associated with the treatment of Hepatitis C
Virus (HCV) treated with Peg-interferon Alpha-2a versus Peg-Interferon Alpha 2b.
METHODS: For an initial distribution of patients it was used as an assumption that
60% of patients had chronic hepatitis and the other had compensated hepatitis.
With this information was developed a Markovmodel with probabilities of disease
evolution. The stages for thismodel from this were: liver cancer, ascites, refractory
ascites, gastrointestinal bleeding, hepatic encephalopathy, liver transplantation
and death. Costs are expressed in US dollars. RESULTS: The highest response rates
were foundwith Peg-Interferon Alpha-2a for genotypes 1, 2 and 3 with a difference
up to 15% compared to Peg-Interferon Alpha-2b. Due to a higher sustained virolog-
ical response rate with Peg-Interferon Alpha-2a, the percentage of patients using
this treatment had a lower probability of falling and developing chronic complica-
tions of the disease. Therefore, the cost of the disease treatment decreases. Also
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